Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
Internal documents show Gilead held off on developing new therapies, such as Descovy, a potentially less toxic version of Truvada.
After advances in HIV therapy, long-acting antiretrovirals and long-term remission are the next frontiers.
But people with HIV are less likely to be diagnosed and treated for insomnia than their HIV-negative peers.
People whose viral load rebounds on Tivicay may not need to switch medications.
For pregnant women with HIV, dolutegravir-based regimens are apparently safest.
Researchers compared regimens prescribed to pregnant women in their second trimester.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
However, an analysis of Swiss people with HIV found no significant change in the suicide rate in more recent years.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Tenofovir disoproxil fumarate is found in Truvada, Viread, Atripla, Complera and Stribild.
Italian researchers randomized half of a group of people on daily Atripla to switch to taking the single-tablet regimen every second day.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.